Tenon Medical, INC 8-K filings

Tenon Medical, Inc. announced a 1-for-35 reverse stock split to comply with Nasdaq listing requirements, effective August 10, 2026.

Tenon Medical, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved several critical proposals including a reverse stock split and auditor ratification.

Tenon Medical announced it has received notice from Nasdaq confirming it has regained compliance with the minimum stockholders equity requirement, following a recent public offering.

Tenon Medical, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders equity requirement following a recent public offering.

Tenon Medical has implemented a 2026 executive compensation plan and extended the consulting agreement for its Executive Chairman.

Tenon Medical, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement for continued listing.

Tenon Medical announced a 90% revenue increase and significant gross margin expansion in Q1 2026, alongside a $4.3 million convertible note financing.

Tenon Medical announced record fourth quarter and full year 2025 financial results, driven by increased revenue and gross profit, alongside key product and intellectual property advancements.

Tenon Medical, Inc. received a notice from Nasdaq regarding its failure to maintain the minimum $1.00 bid price requirement for continued listing.

Tenon Medical, Inc. announced unaudited revenues for Q4 2025 and full year 2025, showing significant year-over-year growth, and set a date for its full financial results release.

Tenon Medical, Inc. announced the successful closing of a $2.85 million private investment in public equity (PIPE) financing to fund operations and growth initiatives.

Tenon Medical, Inc. filed an amended 8-K to provide financial statements and pro forma information for its August 1, 2025 acquisition of SiVantage, Inc.

Tenon Medical, Inc. issued 866,642 restricted stock units to its directors and officers, vesting in two installments in 2026.

Tenon Medical, Inc. stockholders approved the election of seven directors, warrant exercisability, and amendments to its equity incentive plan at its reconvened 2025 Annual Meeting.

Tenon Medical strategically acquired sacroiliac joint assets from SiVantage and SIMPL Medical, expanding its product portfolio and integrating key commercial leadership.

Tenon Medical, Inc. announces a $2.5 million capital raise through a registered direct offering and concurrent private placement priced at-the-market under Nasdaq rules.

Tenon Medical, Inc. has announced a registered direct offering and concurrent private placement with a single healthcare-focused institutional investor, expected to generate gross proceeds of approximately $1.5 million.

Tenon Medical, Inc. is offering new warrants to a holder of existing warrants to incentivize the exercise of those warrants at a reduced price, potentially generating $3 million in gross proceeds.

Tenon Medical, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement after raising approximately $9.634 million through recent equity financing transactions.

Tenon Medical, Inc. successfully priced and closed a public offering, raising approximately $4.5 million to support its commercial activities and general corporate needs.

Tenon Medical, Inc. has entered into a warrant exercise inducement agreement, potentially raising approximately $4.6 million in gross proceeds.

Tenon Medical received a notification from Nasdaq for not meeting the minimum publicly held shares requirement following a recent reverse stock split, but plans to regain compliance through a public offering.

Tenon Medical has finalized the terms for its Series B Preferred Stock issuance, including conversion rights and liquidation preferences, while also amending the terms of its Series A Preferred Stock.

Tenon Medical, Inc. has entered into a securities purchase agreement to sell 86,454 shares of Series B Preferred Stock and warrants to purchase 16,214 shares of common stock for an aggregate offering price of $550,000.

Tenon Medical has appointed Kevin Williamson as its new Chief Financial Officer, effective September 3, 2024, succeeding Steve Van Dick's retirement.

Tenon Medical, Inc. has received a notice from Nasdaq for not meeting the minimum stockholders' equity requirement for continued listing.

Tenon Medical successfully held its 2024 Annual Stockholders Meeting, electing all director nominees and approving several key proposals including amendments to the equity incentive plan and ratification of the independent auditor.

Tenon Medical's Executive Vice President, Finance and Administration, Chief Financial Officer, and Assistant Secretary, Steven Van Dick, has announced his retirement, effective July 31, 2024.

Tenon Medical, Inc. has received a notice from Nasdaq stating that its common stock has failed to maintain the minimum bid price of $1.00 per share, potentially leading to delisting.

Tenon Medical has appointed Kristine Jacques, a seasoned medical device executive, to its Board of Directors, effective March 25, 2024.